MP18-16 POTENTIAL NEW THERAPY AGAINST SUNITINIB-RESISTANT RENAL CELL CARCINOMA

INTRODUCTION AND OBJECTIVE:Temsirolimus and Everolimus, termed rapalogs, have been used as first generation mTOR inhibitors for renal cell carcinoma (RCC). These rapalogs were designed to block onl...